Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Postbiotic Restoration Of the Metabolome Of Moms

Project description

Post-antibiotic products for enhanced maternal resilience

Microbial dysbiosis can lead to behavioural changes, such as increased aggression, which can also affect offspring. Gut bacteria may play a role in influencing these behaviours. A potential solution is a daily post-biotic supplement, similar to prenatal vitamins, which could help restore gut health after antibiotic use during pregnancy and nursing. The ERC-funded BEHAVIOME project has identified a path toward early commercialisation and secured internal support for development. The ERC-funded PRO-MOM project aims to advance this technology through proof-of-concept demonstrations and market research. The project plans to establish a spin-off company to develop post-antibiotic products with venture capital or partnerships. It seeks to create a post-antibiotic supplement aimed at enhancing maternal and neonatal microbiota while reducing behavioral disturbances during the first 1 000 days of life.

Objective

Microbial dysbiosis can lead to behavioral changes including aggressive behavior. Mice treated with antibiotics exhibit increased aggression, as do offspring of mothers given antibiotics only during pregnancy or alternatively only when nursing. Promising results from our lab in flies and mice support our hypothesis that such behaviors are partially affected by gut bacteria and associated metabolic compounds. Pregnancy is associated with reduced immune function and women receive antibiotics during this period for a myriad of reasons. Preclinical trials and clinical research suggest strong effects of these treatments on offspring. A postbiotic to be taken daily, in a manner similar to prenatal vitamins, following antibiotic use during pregnancy and breastfeeding can restore microbiota form and function, towards alleviating changes in offspring behavior. Throughout our ERC-funded research, BEHAVIOME, our approach to exploring the innovation potential of our research is a stepwise process. A direct result of this process was the identification of the ERC Proof of Concept as a viable route to defining the early commercialisation steps, and obtaining internal support to develop and implement the project. Within PRO-MOM, we aim to complete two critical objectives: significant progress on technology development (POC demonstration, in vivo pilot data), and achieving business readiness (market research, business plan, end-user engagement). The outcome of the ERC POC will enable us to take the last step pre-commercialisation, developing market readiness. For commercialization, our plan is to set up a spin-off company that will develop several postbiotic leads, either through funding raised through venture capital, or co-development with other larger companies in the field. With PRO-MOM we will develop a post-antibiotic supplement that promotes maternal-neonatal microbiota restructuring and reduces behavioral disturbances in the critical first 1000 days of life.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-POC

See all projects funded under this call

Host institution

BAR ILAN UNIVERSITY
Net EU contribution
€ 150 000,00
Address
BAR ILAN UNIVERSITY CAMPUS
52900 Ramat Gan
Israel
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)